Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on Octob...
October 13 2020 - 7:00AM
Business Wire
Key Opinion Leader in the Treatment of
Psoriasis to Join the Presentation and Q&A
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address inflammatory, cancer and liver
diseases, today announced it will host a conference call with
investors to provide an update on its Phase III psoriasis study and
the positive interim data analysis and recommendations from the
study’s Independent Data Monitoring Committee (IDMC). Dr. Michael
Goldfarb, M.D., Dermatologist, Beaumont Hospital, Dearborn,
Michigan, U.S., a key opinion leader in the treatment of psoriasis,
will join the call which is scheduled to take place on Thursday,
October 15, 2020 at 4:15 pm EDT.
Piclidenoson, Can-Fite’s lead drug candidate, offers several
potential key benefits over psoriasis treatments currently on the
market. As an oral pill taken twice daily, it offers ease of
administration for patients who tend to prefer oral medications
over injectables. As an oral drug, the Company believes
Piclidenoson may be priced at a significantly lower cost than
injectable biologics, and somewhat lower than the current oral
medication on the market, Otezla®. A 2018 study on psoriasis
patient preferences published in American Health & Drug
Benefits showed the two most important considerations for choosing
a psoriasis drug were route of administration and cost, with oral
administration and lower cost being most preferred.
Piclidenoson has been dosed in over 1,500 patients with an
excellent safety profile in clinical trials to date. In contrast,
the biologics on the market approved to treat psoriasis have black
box warnings. While psoriasis is a serious disease with quality of
life implications for patients, it is not life threatening and
therefore patients recognize that while they need a treatment that
is effective, safety is also a very high priority.
With an estimated 125 million cases worldwide, psoriasis is
considered an immune system problem that causes infections, stress
and is a chronic disease with no cure. The market size for
psoriasis is estimated to be $11.5 billion at the end of 2020.
The call will take place on Thursday, October 15th 2020 at 4:15
pm EDT. Investors in the U.S. are invited to dial 1-877-423-9813.
International investors may dial 1-201-689-8573. The conference ID
is 13711928.
Investors may also participate via webcast:
http://public.viavid.com/index.php?id=141970
A replay of the webcast will be archived on Can-Fite’s website
for a period of time.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, liver, inflammatory disease and
COVID-19. The Company's lead drug candidate, Piclidenoson, is
currently in a Phase III trial for rheumatoid arthritis/psoriasis
and a Phase II study in the treatment of moderate COVID-19.
Can-Fite's liver drug, Namodenoson, is headed into a Phase III
trial for hepatocellular carcinoma (HCC), the most common form of
liver cancer, and successfully achieved its primary endpoint in a
Phase II trial for the treatment of non-alcoholic steatohepatitis
(NASH). Namodenoson has been granted Orphan Drug Designation in the
U.S. and Europe and Fast Track Designation as a second line
treatment for HCC by the U.S. Food and Drug Administration.
Namodenoson has also shown proof of concept to potentially treat
other cancers including colon, prostate, and melanoma. CF602, the
Company's third drug candidate, has shown efficacy in the treatment
of erectile dysfunction. These drugs have an excellent safety
profile with experience in over 1,500 patients in clinical studies
to date. For more information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among
other things, market risks and uncertainties, its product
development efforts, business, financial condition, results of
operations, strategies or prospects. In addition, from time to
time, Can-Fite or its representatives have made or may make
forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words
such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or
“anticipate” or their negatives or other variations of these words
or other comparable words or by the fact that these statements do
not relate strictly to historical or current matters. These
forward-looking statements may be included in, but are not limited
to, various filings made by Can-Fite with the U.S. Securities and
Exchange Commission, press releases or oral statements made by or
with the approval of one of Can-Fite’s authorized executive
officers. Forward-looking statements relate to anticipated or
expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to
risks and uncertainties that could cause Can-Fite’s actual results
to differ materially from any future results expressed or implied
by the forward-looking statements. Many factors could cause
Can-Fite’s actual activities or results to differ materially from
the activities and results anticipated in such forward-looking
statements. Factors that could cause our actual results to differ
materially from those expressed or implied in such forward-looking
statements include, but are not limited to: our history of losses
and needs for additional capital to fund our operations and our
inability to obtain additional capital on acceptable terms, or at
all; uncertainties of cash flows and inability to meet working
capital needs; the impact of the recent outbreak of coronavirus;
the initiation, timing, progress and results of our preclinical
studies, clinical trials and other product candidate development
efforts; our ability to advance our product candidates into
clinical trials or to successfully complete our preclinical studies
or clinical trials; our receipt of regulatory approvals for our
product candidates, and the timing of other regulatory filings and
approvals; the clinical development, commercialization and market
acceptance of our product candidates; our ability to establish and
maintain strategic partnerships and other corporate collaborations;
the implementation of our business model and strategic plans for
our business and product candidates; the scope of protection we are
able to establish and maintain for intellectual property rights
covering our product candidates and our ability to operate our
business without infringing the intellectual property rights of
others; competitive companies, technologies and our industry;
statements as to the impact of the political and security situation
in Israel on our business; and risks and other risk factors
detailed in Can-Fite’s filings with the SEC and in its periodic
filings with the TASE. In addition, Can-Fite operates in an
industry sector where securities values are highly volatile and may
be influenced by economic and other factors beyond its control.
Can-Fite does not undertake any obligation to publicly update these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201013005454/en/
Can-Fite BioPharma Motti Farbstein info@canfite.com
+972-3-9241114
US Investors: Dave Gentry RedChip Companies Inc.
Dave@redchip.com 407-491-4498
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2023 to Apr 2024